Onconetix Extends Up to $5 Million Bridge Financing to Realbotix Ahead of Acquisition

Onconetix Inc. has provided Realbotix LLC with a bridge financing facility of up to $5 million as the companies work toward completing Onconetix’s pending acquisition of the humanoid robotics business. The facility starts with a $2.5 million advance intended to support Realbotix’s growth and working capital needs before closing.

The bridge is structured around the outcome of the acquisition. It does not bear interest while the share exchange remains pending, and the facility and related obligations will be automatically cancelled and discharged if the acquisition closes. If the share exchange agreement is terminated instead, interest begins accruing at 12% a year from the termination date.

Onconetix said the cash required at closing will also be reduced by the amount of principal advanced under the facility plus an additional $500,000. The company’s September 14 announcement does not state that the entire $5 million has been drawn. It identifies $2.5 million as the initial advance and describes $5 million as the maximum aggregate principal available under the bridge.

The bridge has different economics depending on whether the acquisition closes

The financing gives Realbotix access to cash before Onconetix has completed its purchase of the business, but its repayment mechanics are tied closely to that closing. During the pre-closing period, no interest accrues. If Onconetix completes the acquisition, the bridge debt disappears rather than remaining as a separate obligation of Realbotix after closing.

If the acquisition fails to close and the share exchange agreement is terminated, the bridge takes on a conventional debt feature: interest begins accruing at 12% annually from the termination date. The September 14 release does not describe an earlier interest charge for the period before termination, and it does not disclose a maturity date, collateral package or other repayment terms for the note in the release itself.

The reduction in cash required at closing is another part of the structure. Onconetix said the closing cash requirement will fall by the principal it has advanced to Realbotix plus $500,000. That provision links the pre-closing funding to the acquisition economics, but the release does not provide a revised closing-cash figure or quantify how the adjustment changes Onconetix’s expected net cash position at closing.

The acquisition would move Realbotix LLC into Onconetix

Onconetix agreed in February to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly owned subsidiary of Realbotix Corp. The agreed structure is an all-stock share exchange. Realbotix LLC houses the commercial humanoid robotics operations that research, design, build and manufacture AI-powered robots for uses including customer service, healthcare, education, hospitality and entertainment.

Under the acquisition terms disclosed earlier this year, the seller is expected to own 75% to 90% of Onconetix’s fully diluted shares after closing, with the final percentage determined by Onconetix’s net cash. Onconetix’s latest quarterly filing says the seller would own 90% if net cash is at least $12.5 million but below $15 million, 85% from $15 million to below $18 million, 80% from $18 million to below $20 million, and 75% if net cash is at least $20 million.

The same Form 10-Q filed with the SEC states that Realbotix, its parent and the seller are not required to complete the acquisition unless Onconetix has at least $12.5 million of net cash at closing. The agreement also requires Onconetix shareholder approval and other customary approvals and conditions. Either side may terminate the agreement if closing has not occurred by November 30, 2026, unless the terminating party caused the failure through a breach. That date automatically extends to December 20 if all closing conditions other than the net cash condition have been satisfied.

Those conditions make the bridge financing distinct from the acquisition itself. The $2.5 million already advanced supports Realbotix while the closing process continues, but it does not establish that the remaining acquisition conditions have been met. Onconetix’s September 14 release continues to describe the acquisition as pending.

Onconetix is deploying cash while managing its own funding needs

The bridge is also notable against Onconetix’s recent liquidity disclosures. At June 30, the company reported about $5.9 million of cash and a working-capital surplus of about $3.6 million. It used roughly $4.0 million of cash in operating activities during the first six months of 2026, and said its cash balance was approximately $5.4 million as of August 10.

Onconetix has said it will need additional capital to fund operations and support strategic initiatives, including the Realbotix acquisition. In late July it entered a new equity line arrangement and issued Series F preferred stock. The quarterly filing says the Series F sale had an aggregate purchase price of about $30.25 million but generated net cash proceeds of about $249,600 because a $30 million commitment fee for the equity line was applied toward the preferred-stock purchase. The equity line can provide access to additional capital subject to its contractual and Nasdaq-related limits.

The company’s August filing also warned that available funding might not be sufficient to sustain operations and complete the Realbotix acquisition on the contemplated timetable. The initial $2.5 million bridge advance therefore represents a meaningful use of cash, although the September 14 announcement does not identify the specific source used to fund that advance. It would be inaccurate to assume from the public materials alone that the money came from any particular financing program.

The next concrete milestone remains the acquisition closing. Before that can occur, Onconetix must satisfy the applicable shareholder, regulatory and financial conditions, including the minimum net cash requirement. If the acquisition closes, the bridge obligations are cancelled as provided in the note. If the share exchange is terminated, the 12% interest provision begins to apply from the termination date.